Disease-information
JAMA Network: Published on June, 2022Montelukast, the most widely used
leukotriene-modifying agent (LTMA), is a selective leukotriene receptor
antagonist and is currently indicated for prophylactic and chronic treatment of
asthma, relief of symptoms of allergic rhinitis, and acute prevention of
exercise-induced bronchoconstriction.This propensi...
Nature Medicine: Published on November, 2022Obesity is a chronic, relapsing
disease with a substantial morbidity, mortality, and healthcare burden. Drug
interventions for the treatment of obesity provide a potential valuable adjunct
to lifestyle interventions, which often achieve only limited weight loss that
is difficult to maintain. Semagluti...
ACP Journals: Annals of Internal Medicine: Published on
November, 2022Current guidelines recommend using
direct oral anticoagulants (DOACs) over warfarin in patients with atrial
fibrillation (AF), but head-to-head trial data do not exist to guide the choice
of DOAC.The aim
of the study is to do a large-scale comparison between all DOACs
(apix...
Lung Function & the Risk of Exacerbation in Patients with COPD Treated With the β-Blocker Metoprolol
Annals of the American Thoracic Society: Published on October, 2022Chronic obstructive pulmonary disease (COPD) is a leading
cause of death worldwide [1, 2]. COPD exacerbations that are related to poor
prognosis and severe COPD exacerbations requiring hospital admission.Beta-adrenoceptor (β-ADR) antagonists, or “beta blockers,”
are indicated for...
FDA News Release: Published on November, 2022Type one diabetes mellitus (T1DM)
is an autoimmune disease characterized by gradual destruction of beta cells in
islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody,
which have beneficial effects for T1DM patients.The U.S. Food and Drug
Administration (FDA) has approved tepl...
Coronavirus disease 2019 (COVID-19)
is one of the most significant pandemics in human history caused by the virus
known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 has infected >530 million people, of which >6.3 million have
died since June 23, 2022. Recent research has indicated that
COVID-19 might be a risk fa...
The Lancet: Published on October, 2022Hypertension, or high blood
pressure, is a key risk factor for cardiovascular disease worldwide. Previous clinical trials supporting
the cardiovascular benefits of antihypertensive therapy primarily use
conventional morning dosing. Additionally, cardiovascular events
are temporally associated with the morni...
Neurology (American Academy of Neurology) Journal: Published on March,
2022Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) can cause long-term disability (long COVID)
with new neurologic manifestations after even mild infections. Reports of peripheral
neuropathy include Guillain-Barré syndrome, mononeuritis multiplex, brachial
ple...
European Heart Journal: September, 2022Cardiovascular (CV) disease (CVD) is the leading cause of
morbidity and mortality worldwide, despite continuous improvement of medical
treatment, diagnosis, and risk factor control. It has been clearly
demonstrated that statin therapy confers significant mortality and morbidity
benefits in both the primary...
The Lancet: Published on September, 2022A
promising malaria vaccine was up to 80% effective at preventing the disease in
young children who received a booster shot at one year following a primary
three-dose regime maintained high efficacy against malaria, and continued to
meet the World Health Organization’s Malaria Vaccine Technology Roadmap g...
Journal of the American
Heart Association (AHA): Published on November, 2022Sleep, alongside diet and physical activity (PA), is one of
the 3 pillars of health, but unlike other health behaviors, healthy sleep is
not included in the American College of Cardiology/American Heart Association
(AHA) cardiovascular disease (CVD) prevention guideline...
Nature Medicine: Published on November, 2022Obesity is a chronic, relapsing
disease with a substantial morbidity, mortality, and healthcare burden. Drug
interventions for the treatment of obesity provide a potential valuable adjunct
to lifestyle interventions, which often achieve only limited weight loss that
is difficult to maintain. Semagluti...
